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of EQ-5D, the frequency of T2DM patients responding as having “some problem” 
and “extreme problem” was 4.6% and 1.6% for mobility, 7.9% and 1.4% for self-
care, 13.9% and 1.7% for usual activities, 27.5% and 1.1% for pain/discomfort, and 
26.6% and 1.3% for anxiety/depression, respectively. The mean VAS score (±SD) of 
patients was 70.4 ± 15.1. CONCLUSIONS: The rates of T2DM patients with “some 
problem” in pain/discomfort, and anxiety/depression were relatively high; rate with 
“extreme problem” for usual activities was also higher than other dimensions. The 
results of 5D were consistent with the low VAS score. These ﬁ ndings imply that there 
was a signiﬁ cant impact on the health status of T2DM patients with OADs therapy 
due to pain/discomfort, and anxiety/depression. It underscores the urgent need to 
adopt effective measures toward prevention and control of diabetes to improve 
patients’ quality of life.
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OBJECTIVES: The objective of this study was to elicit quality-adjusted life-year 
(QALY) weights for the different severity levels of diabetic retinopathy (DR) and to 
evaluate the adequacy of using certain health-related quality of life (HRQoL) instru-
ments for this purpose. METHODS: The study population comprises 151 patients 
with diabetes (type 1 and 2) that either attended the eye clinic at Linköping University 
Hospital or were registered at any of the two vision centrals in Östergötland County, 
Sweden. Participants were interviewed over the phone using time trade-off (TTO) 
questions, the EuroQol Health Questionnaire (EQ-5D), the Health Utilities Index 
Mark III (HUI-3) and the National Eye Institute Visual Function Questionnaire (NEI-
VFQ-25). The effect of other variables than DR on QALY weights was investigated 
using ANCOVA and the generic instruments were tested for correlation with NEI-
VFQ-25. RESULTS: The ranges of the QALY weights estimated with the three generic 
instruments were for no DR, BR, PDR, maculopathy and legal blindness 0.81–0.88, 
0.72–0.78, 0.75–0.82, 0.74–0.81 and 0.39–0.68 respectively. In general, the differ-
ences in QALY weights between the different severity levels were reduced when 
adjusted for clinical characteristics and co-morbidities. The difference in QALY 
weights between the patients with no DR and legal blindness was signiﬁ cant for all 
instruments. The correlations between the results from NEI-VFQ-25 and TTO, EQ-5D 
score, EQ-5D VAS and HUI-3 were 0.27, 0.31, 0.38 and 0.68 respectively. CONCLU-
SIONS: This study presents QALY weights for different severity levels of DR, which 
can be used in cost-effectiveness analyses of interventions directed to DR. Of the 
instruments we used, HUI-3 seems to be the most sensitive to changes in HRQoL due 
to progression of DR.
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OBJECTIVES: The QoL-AGHDA is the ﬁ rst true quality of life (QoL) measure for 
adult growth hormone deﬁ ciency and is widely used in clinical practice and trials. In 
the UK NICE advises that scores on the QoL-AGHDA should be used to guide treat-
ment selection. The scale has good psychometric properties and has been shown to 
be responsive to changes in disease severity. The objective of the study was to adapt 
the QoL-AGHDA for the Czech Republic, Poland, Serbia, Slovakia and Brazil. 
METHODS: The adaptation in each country required three stages: Translation, cogni-
tive debrieﬁ ng and a validation survey. The dual panel translation method was used 
to ensure the items were translated accurately and expressed in everyday language. 
Cognitive-debrieﬁ ng interviews with local patients assessed face and content validity. 
The validation survey tested the psychometric properties of the new scales and 
included the Nottingham Health Proﬁ le (NHP) as a comparator measure. RESULTS: 
Validation data are not available for Slovakia. Mean scores on the new versions of 
the QoL-AGHDA ranged from 6.2 to 11.8 (maximum possible = 25). Internal con-
sistency ranged from 0.89–0.91 and test-retest reliability from 0.88–0.93. QoL-
AGHDA scores were statistically signiﬁ cantly related to; perceived general health and 
level of fatigue in the Czech Republic, perceived physical activity and level of fatigue 
in Poland and Serbia and to perceived general health and rated QoL in Brazil. Across 
the countries mean correlations with NHP sections were (as expected) highest with 
energy level and emotional reactions (correlations 0.68–0.83) and lowest with sleep 
disturbance and pain (correlations 0.38–0.46). CONCLUSIONS: This study indicates 
that (with the exception of Slovakia which requires further validation) the new lan-
guage versions of the QoL-AGHDA meet the standards of the original UK version 
and the other 9 existing versions. The new adaptations represent valid and reliable 
tools for measuring QoL in international clinical trials.
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OBJECTIVES: Hypoglycaemia can be a side effect of glucose-lowering treatment in 
patients with type 2 diabetes (T2D) that may counterbalance the beneﬁ cial effects of 
diabetes control. PANORAMA is a large (n = 5156) pan-European cross-sectional 
survey (NCT00916513) of patients assessing patient reported outcomes and glycaemic 
control. This subgroup analysis compared rates of severe and non-severe hypoglycae-
mic events in patients taking different pharmacological treatment regimens. 
METHODS: Patients with T2D were randomly or consecutively selected from medical 
practices in eight countries. Patients were aged ≥40 years, with T2D diagnosed >1 
year and a clinic medical record available >1 year. All patients received dietary/exercise 
advice and most were also taking either oral antidiabetic drugs (OADs) and/or inject-
ables (insulin and/or GLP-1 receptor agonists). Patients included in this subgroup 
analysis had been taking the same pharmacological treatment regimen for ≥12 months. 
Patient-reported frequency of severe (symptomatic episodes requiring external assis-
tance) and non-severe hypoglycaemic episodes in the past year were examined. 
RESULTS: In this subgroup analysis 3106 patients were evaluated including: 1346 
taking only OADs without secretagogues; 1452 taking only OADs including secreta-
gogues (sulphonylurea/glinides) and 308 on insulin alone. The percentages of patients 
experiencing >1 non-severe hypoglycaemic episode in each treatment group were: 
8.9% for patients taking OADs without secretagogues; 17.5% for patients taking 
OADs including secretagogues and 47.4% for patients using insulin alone. The dif-
ferences between these three treatment categories (pair-wise comparisons) were highly 
signiﬁ cant (P < 0.001). The percentage of patients reporting ≥1 severe hypoglycaemic 
episode was greater for OADs including secretagogues versus no secretagogues (3.0% 
versus 1.3%; P = 0.011) and for insulin alone versus OADs including secretagogues 
(13.7% versus 3.0%; P < 0.001). CONCLUSIONS: Among patients with T2D on 
glucose-lowering medication, rates of non-severe and severe hypoglycaemic episodes 
were lowest amongst patients treated with OADs not including secretagogues and 
highest among patients treated with insulin alone.
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OBJECTIVES: Understanding the perspectives of Type 2 Diabetes (T2D) patients on 
hypoglycemia is important, in order to understand the burden of the disease and its 
treatment, and to develop improved outcome measures. The goal of this project was 
to identify key hypoglycemia-related concepts among T2D patients using qualitative 
interviews. METHODS: Participants were 19 T2D patients who were prescribed: 1) 
an oral anti-diabetic (OAD) and had been diagnosed with T2D in the past 3 years (n 
= 11); 2) a sulfonylurea (SU) or thiazolidinedione (TZD) that caused weight gain, 
following the failure of an OAD in the last year (n = 5); or 3) an incretin mimetic that 
caused weight loss, following the failure of an OAD in the last year (n = 3). One-hour 
in-person interviews were conducted using a semi-structured interview guide. Inter-
views were coded using ATLAS.ti software and code frequency was used to identify 
key experiences. RESULTS: Patients were 54.4 years of age on average and 63% were 
female. Tremor, sweating, and dizziness were the most commonly noted symptoms of 
hypoglycemia; all ﬁ ve of the patients on an SU or TZD reported experiencing tremor. 
Patients reported concerns about rare, severe events, such as passing out. Patients 
generally did not report that their lives were substantially impacted by hypoglycemia, 
but completing compensatory behaviors to prevent hypoglycemia emerged as an 
important theme (keeping glucotabs in multiple locations, eating large meals). CON-
CLUSIONS: Hypoglycemia has a negative impact on patients with T2D. Many report 
experiencing hypoglycemia symptoms, and, although T2D patients do not often report 
anxiety about hypoglycemia, several reported concerns about the consequences of 
severe events. Patients also engage in compensatory behaviors, which suggests that 
avoiding hypoglycemia is important. Further reﬁ nement of the concepts associated 
with the patient’s experience of hypoglycemia may yield new PRO instruments that 
can be implemented in clinical trials with T2D patients.
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OBJECTIVES: Maintaining a healthy weight is important in the management of 
T2DM. We investigated the relationship between weight and patient concerns in rela-
tion to overall health-related well-being and function among those with T2DM. 
